Palbociclib and Ponatinib Suppress Acute Myeloid Leukemia in Patient-Derived Xenograft

Daniel Busa,Tomas Loja,Ivana Jeziskova,Adam Folta,Jiri Mayer,Martin Culen

Blood（2021）

引用 1|浏览14

暂无评分

摘要

Aims: Palbociclib, a breast cancer approved CDK4/6 inhibitor, and ponatinib, a BCR/ABL1 inhibitor with a multi-kinase activity approved for chronic myeloid and acute lymphoid leukemia, were previously shown to be effective in vitro against acute myeloid leukemia (AML). Here, we aimed to test this effect in a patient-derived xenograft model.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要